{"id":"NCT04924062","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study","officialTitle":"A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-10","primaryCompletion":"2022-12-15","completion":"2025-03-25","firstPosted":"2021-06-11","resultsPosted":"2023-12-26","lastUpdate":"2025-04-17"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Biliary Tract Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar"]},{"type":"DRUG","name":"Cisplatin","otherNames":["Platinol®","Platinol®-AQ"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A (Pembrolizumab+Gemcitabine+Cisplatin)","type":"EXPERIMENTAL"},{"label":"Arm B (Placebo+Gemcitabine+Cisplatin)","type":"PLACEBO_COMPARATOR"}],"summary":"In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 29 months","effectByArm":[{"arm":"Arm A (Pembrolizumab+Gemcitabine+Cisplatin)","deltaMin":14.1,"sd":null},{"arm":"Arm B (Placebo+Gemcitabine+Cisplatin)","deltaMin":9.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":22,"countries":["China"]},"refs":{"pmids":["40154623"],"seeAlso":["https://www.merckclinicaltrials.com","https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=3475-966&kw=3475-966"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":74},"commonTop":["Anaemia","White blood cell count decreased","Neutrophil count decreased","Platelet count decreased","Nausea"]}}